Soerensen, Anne V <br/><br/>
Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.  [electronic resource] 

 -  European urology  Sep 2015 
 - 516-22 p.  digital 
<br/><br/> Publication Type: Journal Article; Observational Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-7560 
<br/><br/><label>Standard No.: </label>10.1016/j.eururo.2014.12.017  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Ambulatory Care--economics<br/>Angiogenesis Inhibitors--economics<br/>Antineoplastic Agents--economics<br/>Bevacizumab--economics<br/>Carcinoma, Renal Cell--drug therapy<br/>Costs and Cost Analysis<br/>Denmark<br/>Drug Costs<br/>Efficiency<br/>Employment--economics<br/>Everolimus--economics<br/>Female<br/>Fluorouracil--economics<br/>Health Care Costs<br/>Hospitalization--economics<br/>Humans<br/>Immunologic Factors--economics<br/>Indoles--economics<br/>Interferon-alpha--economics<br/>Interleukin-2--economics<br/>Kidney Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Metastasis--drug therapy<br/>Niacinamide--analogs & derivatives<br/>Phenylurea Compounds--economics<br/>Protein Kinase Inhibitors--economics<br/>Pyrroles--economics<br/>Radiography--economics<br/>Radiotherapy--economics<br/>Registries<br/>Sirolimus--analogs & derivatives<br/>Sorafenib<br/>Sunitinib